| Date | Room | Time | Topic | Lecturer/Expert | Afilliation (1) |
|--|------------|----------------|--|----------------------------|-------------------------------|
| | | 9-10:15 am | Introduction to the Course | Jagesh Shah, PhD | HMS/BWH/HST |
| Day 1: MON 13th June, | ARM | 10:30-12 pm | Unmet Medical Needs | Mark Fishman, MD | Novartis |
| | | | | Paul Ridker, MD | BWH |
| | 108 | 1-3 pm | Statins and cholesterol- | David Cohen, MD, PhD | BWH |
| 2016 | | - | reducing drugs | Donna Polk, MD, MPH | BWH |
| 2010 | | 2.5 | Unmet Medical Needs | Catherine Dubreuil, PhD | HMS |
| | | 3-5 pm | Exercise | Jagesh Shah, PhD | HMS/BWH/HST |
| | | 9-10 am | Patient Visit - Polycystic Kidney Disease (PKD) | Mike and Samantha Fratus | |
| | | | | Julie Jonassen, PhD | UMASS Med |
| | | | | Theodore Steinman, MD | BIDMC/BWH |
| | | 10:15 am-12 pm | PKD case panel | Julie Jonassen, PhD | UMASS Med |
| Day 2: | | | | Jagesh Shah, PhD | HMS/BWH/HST |
| TUE 14th | ARM 108 | | | Theodore Steinman, MD | BIDMC/BWH |
| | | | | Oxana Beskrovnaya, PhD | Genzyme |
| June, | | 1-2 pm | Introduction to Gleevec case | Megan Mittelstadt, PhD | HMS |
| 2016 | | | | Jeff Karp, PhD | BWH |
| | | 2-4 pm | How do research discoveries get turned into therapies? | Lauren Foster, DSc | MIT Tech. Licensing Office |
| | | | | Geoffery von Maltzahn, PhD | Flagship VentureLabs |
| Day 3: WED | ARM 108 | 9-10 am | Drug Screening and Structure- based drug design | Sara Buhrlage, PhD | DFCI |
| 15th June, | | 10:10-11:30 am | Drug Pharmacology | Tim Mitchison, PhD | HMS |
| | | 11:30-12:30 pm | Pre-clinical animal toxicity | Tim McLachlan, PhD | Novartis |
| 2016 | | 1-4 pm | Break work on their Gleevec Case | | |
| | ARM 108 | 9-10:45 am | Models of disease | Larry Benowitz, PhD | BCH |
| | | | | Wolfram Goessling, MD, PhD | BWH |
| Day 4: THU 16th June, 2016 | | | | Sanyal Subhabrata, PhD | Biogen IDEC |
| | | | | Kevin Croce MD, PhD | BWH |
| | | 11 am-12:15 pm | Break work on their Gleevec Case | | |
| | | 1-3 pm | When drugs stop working - Drug Resistance | Alyssa Letourneau, MD, MPH | MGH |
| | | | | Don Coen, PhD | HMS |
| | | | | Dan Kuritzkes, MD | BWH |
| | | | | Anna Farago, MD, PhD | MGH |
| | | 3:15-5 pm | Moving into humans: Clinical trial design | Mark Goldberg, MD | BWH |
| Day 5: FRI 17th June, 2016 | ARM 108 | 9-10:30 am | Phase I: Testing Drug Toxicity in Healthy Humans | Jennifer Wheler, MD | Novartis |
| | | 10:30-12 pm | Phase II: Surrogate endpoints in a tuberculosis drug | Eric Rubin, MD, PhD | HSPH/HMS |
| | | 1-2 pm | Phase III: HIV vaccines and cohort selection | Filippos Porichis, PhD | The Ragon Institute |
| | | 2-5 pm | Gleevec case presentations | Megan Mittelstadt, PhD | HMS |
| | | | | Andrew Wylie, PhD | Novartis |
| | | | | Daniel DeAngelo, MD, PhD | DFCI |

| MOIN 20th June, 2016TMEC L-008Instruction in the interval of | Date | Room | Time | Торіс | Lecturer/Expert | Afilliation (1) |
|--|----------------------|---------------|-------------------|---|----------------------------|--------------------------------------|
| Day 6: MON 2016FMUCR LOBS0:30-11:30 amPattern accard approval scasefeftrey KauffmanAdenoid Cystic Carcinoma Research Carcinoma Research20161.30-12 pmIntroduction to Alzheimer's caseCatherine Dubreuil, PhDHMS20161:30-12 pmIntroduction to Alzheimer's caseCatherine Dubreuil, PhDHMS20162:30-3:30 pmAD Case workNubar Afeyan, PhDMIT20163:30-5 pmPrecision Medicine Precision MedicineMark Trusheim, PhDBWH10:30 am-12:30 pmVioxx CaseMPH1Aaron Kesselheim, MD, JD, MPH1BWH10:30 am-12:30 pmVioxx CaseMPH1Aaron Kesselheim, MD, JD, MPH1BWH20161:30-4:00 pmChallenges in medical device developmentFred Schoen, MD, PhDBWH/HMS/HST20171:0:30 amBiomarkersVishal Vaidya, PhDBWH2018Modell 10:45 am-12 pmPharmacogenonicsPeter Shaw, PhDMerck2016TMEC 1-00:51:3 pmAlzheimer's Disease case presentation and wrap upDoin Chen, MD, PhDMGH20161:30-2:45 pmAlzheimer's Disease case presentation and wrap upDoine Walsh, PhDBWH20171:30-2:45 pmAlzheimer's Disease case presentation and wrap upDoinic Walsh, PhDBWH20161:30-2:45 pmAlzheimer's Disease case presentation and wrap upShekar Shetty, PhDDiagnostics for All Catherine Dubreuil, PhD20161:00:00 am-12:30 pmCheckpoint Inhibition in the Tr | MÖN 20th June, | | 9-9:30 am | Looking back and forward | Jagesh Shah, PhD | HMS/BWH/HST |
| Day 6: MON 2016TMEC 1-0089:30-17:30 amscience and approvalJeffrey KauffmanAdenoid Cystic Carcinoma Research Carcinoma Research Carcinoma Research2016TMEC | | | | science and approval | Ed Harlow, PhD | |
| 20th June, 201611:30-12 pmIntroduction to Alzhermer's caseCatherine Dubreuil, PhDHMS20161-2:30 pmTBDNoubar Afeyan, PhDHagship Ventures20163:0-3:30 pmAD Case work20173:0-5 pmAdaptive Licensing in Precision MedicineMark Trusheim, PhDBWH2018THE 1:0:30 am-12:30 pmPhase IV: PharmacovigilanceKrista Huybrechts, PhDBWH2016THE 1:0:30 am-12:30 pmViox CaseAaron Kesselheim, MD, JD, MPHBWH20161:0:30 am-12:30 pmViox CaseViox CaseVior Case20161:0:30 am-12:30 pmChallenges in medical device developmentFed Schoen, MD, PhDBWH/HMS/HST20161:0:30 am-12:30 pmChallenges in medical device developmentPare Shoen, MD, PhDBWH20169:10:30 amBiomarkersViskal Vaidya, PhDBWH20161:0:30 amBiomarkers and companion diagnosticsBoris Juelg, MD, PhDMGH/The Ragon Institute20161:0:20 pmMarkerdiagnosticJohn Chen, MD, PhDMGH/The Ragon Institute2016TMEC 1:0:20 pmAlzheimer's Disease case presentation and wrap upShekar Shetty, PhDBWH20161:0:20 pmAlzheimer's Disease case presentation and wrap upFBDTBD2016TMEC 1:0:0 am-12:30 pmAlzheimer's Disease case presentation and wrap upFBDIBM20161:0:0:0 am-12:30 pmAlzheimer's Disease case presentation and wrap upF | | | 9:30-11:30 am | | Jeffrey Kauffman | Adenoid Cystic Carcinoma Research |
| 2016 Image: Part of the probability of t | | | - | case | , | |
| Image: biologic biologi | | | 1 | | Noubar Afeyan, PhD | Flagship Ventures |
| Image: Solution of the section of t | | | 2:30-3:30 pm | | | |
| Day 7: TUE 21th 2016TMEC | | | * | Precision Medicine | | |
| Day 7: TUE 2016TMEC TUE 201610:30 am-12:30 pmVioxx CaseMPHDWH10:30 am-12:30 pmVioxx CaseMPHKrista Huybrechts, PhDBWHJune, 20161:30-4:00 pmChallenges in medical device developmentFred Schoen, MD, PhDBWH/HMS/HSTDay 8: VED 22nd June, 20169-10:30 amBiomarkersVishal Vaidya, PhDBWHModell 10:45 am-12 pmPharmacogenomicsPeter Shaw, PhDMerckMVED 22nd June, 20161-3 pmPharmacogenomicsPeter Shaw, PhDMerckModell 10:45 am-12 pmHIV Biomarkers and companion diagnosticsBoris Juelg, MD, PhDMGH/The Ragon InstituteDay 9: THU 23rd June, 2016FMEC 1-30-2:45 pmAlzheimer's Disease case presentation and wrap upTBDTBDTMEC 14:00-249am-12:30 pmAlzheimer's Disease case presentation and wrap upTBDTBDTABC 14:00-241:30-2:45 pmPaper-based point of care diagnosticsShekar Shetty, PhDDiagnostics for All Dominic Walsh, PhD34:30 pmCheekpoint Inhibition in the Treatment of CancerEdward Garmey, MDAlacrita Consulting, LCFR1 20161:030 am-12 pmWhy Highly Effective Drugs Are Not Enough: An Affordable Solution to Eliminating HCVAnn Kwong, PhDRagon Institute/MGH20161:030 am-12 pmHIV and Cryptococcal Meningitis: Implementing a low cost point of care assay for early detection and preventionAnn Kwong, PhDRagon Institute/MGH <t< td=""><td rowspan="5">TUE 21th June,</td><td></td><td>9-10:15 am</td><td>Phase IV: Pharmacovigilance</td><td>-</td><td>BWH</td></t<> | TUE 21th June, | | 9-10:15 am | Phase IV: Pharmacovigilance | - | BWH |
| 21th June, 2016L-008L:30-4:00 pmChallenges in medical device developmentFred Schoen, MD, PhDBWH/HMS/HST20161:30-4:00 pmHuman Genetics and the Discovery of New MedicinesDavid Altshuler, MD, PhDVertex PharmaceuticalsDay 8: WED | | | 10:30 am-12:30 pm | Vioxx Case | MPH | |
| June, 20161:30-4:00 pmHuman Genetics and the Discovery of New MedicinesFred Schoen, MD, PhDBWH/HMS/HSTPay 8: WED June, 20169-10:30 am HodellBiomarkersDavid Altshuler, MD, PhDVertex PharmaceuticalsModell June, 20161-3 pmPharmacogenomicsPeter Shaw, PhDMerckModell June, 20161-3 pmHIV Biomarkers and companion diagnosticBoris Juelg, MD, PhDMGH/The Ragon InstituteDay 9: THU June, 2016TMEC L-0079am-12:30 pmHIV Biomarkers (agnostic)John Chen, MD, PhDMGH1:30-2:45 pmPager-based point of care diagnosticsShekar Shetty, PhDBWH1:30-2:45 pmPager-based point of care diagnosticsShekar Shetty, PhDDiagnostics for All Dominic Walsh, PhD20161:30-2:45 pmPager-based point of Care diagnosticsShekar Shetty, PhDDiagnostics for All Alacrita Consulting, LC20161:30-2:45 pmPager-based point of Care diagnosticsShekar Shetty, PhDDiagnostics for All Pominic Walsh, PhD20161:30-2:45 pmPager-based point of Care diagnosticsShekar Shetty, PhDDiagnostics for All Pominic Walsh, PhD20161:30-2:45 pmPager-based point of Care diagnosticsShekar Shetty, PhDDiagnostics for All Pominic Walsh, PhD20161:30-2:45 pmPager-based point of Care are to CanceerShekar Shetty, PhDDiagnostics for All Pominic Walsh, PhD20161:30-2:45 pmPager-based point of Care are tor care are tor c | | | | | Krista Huybrechts, PhD | BWH |
| Day 8: WED 22nd June, 20169-10:30 am 10:45 am-12 pmDiscovery of New Medicines Discovery of New MedicinesDavid Altishuler, MD, PhDPharmaceuticalsPay 8: WED 22nd June, 2016Modell 10:45 am-12 pm9-10:30 am PharmacogenomicsBoris Juelg, MD, PhDMGH/The Ragon Institute10:45 am-12 pmPharmacogenomics companion diagnosticsPeter Shaw, PhDMerck20161:3 pmImaging as a biomarker/diagnosticJohn Chen, MD, PhDMGH/The Ragon Institute2016TMEC 1:007 | | | 1:30-4:00 pm | development | Fred Schoen, MD, PhD | |
| Day 8: WED 2016Modell 100AIot45 am-12 pmPharmacogenomicsPeter Shaw, PhDMerck10:45 am-12 pmHIV Biomarkers and companion diagnosticsBoris Juelg, MD, PhDMGH/The Ragon Institute2016-3 pmImaging as a biomarker/diagnosticJohn Chen, MD, PhDMGHDay 9: THU 23rd June, 2016-4:30 pmAlzheimer's Disease case presentation and wrap upTBDTBD1:30-2:45 pmPaper-based point of care diagnosticsShekar Shetty, PhDDiagnostics for All1:30-2:45 pmPaper-based point of Care diagnosticsShekar Shetty, PhDDiagnostics for All2016-4:30 pmCheckpoint Inhibition in the Treatment of CancerEdward Garmey, MDAlacrita Consulting, LLCFRI 2016-10:15 amWhy Highly Effective Drugs Are Not Enough: An Affordable Solution to Eliminating HCVAnn Kwong, PhDRagon Institute/MGHFRI 2016-2:30 pmHIV and Cryptococcal Meningitis: Implementing a low cost point of care assay for early detection and preventionTariro Makadzange, MD, PhDRagon Institute/MGH2016-2:30 pmBioengineering of circulating a Use; Formulating a strategyDavid BalekdjianBruckner Group2:30-4 pmBioengineering of circulating tumer cell microchip: from concept-to-clinical trialsMehmet Toner, PhDHMS/MGH/HST | | | - | Discovery of New Medicines | | Pharmaceuticals |
| WED 22nd June, 2016Model10.49 am 12 pmHarmacogenomes receivance (ampaice)Preceivance (ampaice)Metec1-3 pm1-3 pmHIV Biomarkers and companion diagnosticsBoris Juelg, MD, PhDMGH/The Ragon Institute20161-3 pmImaging as a biomarker/diagnosticJohn Chen, MD, PhDMGHDay 9: 23rd June, 2016TMECAlzheimer's Disease case presentation and wrap upTBDTBDTHU 23rd June, 20161:30-2:45 pmAlzheimer's Disease case presentation and wrap upShekar Shetty, PhDDiagnostics for All20161:30-2:45 pmPaper-based point of care diagnosticsShekar Shetty, PhDDiagnostics for All20161:30 pmCheckpoint Inhibition in the Treatment of CancerFree Not Enough: An Afordable Solution to Eliminating HCVAnn Kwong, PhDRagon Institute/MGH2016TMEC10:30 am-12 pmHIV and Cryptococcal Mennigitis: Implementing a low co | Day 9. | | | | | |
| 22 nd June, 2016Modell 100A1-3 pmHIV Biomarkers and companion diagnosticsBoris Juelg, MD, PhDMCH/The Ragon Institute20163-4:30 pmImaging as a biomarker/diagnosticJohn Chen, MD, PhDMGHDay 9: THU 23rd June, 2016Pam-12:30 pmAlzheimer's Disease case presentation and wrap upTBDTBD1:30-2:45 pmPaper-based point of care diagnosticsShekar Shetty, PhDDiagnostics for All1:30-2:45 pmPaper-based point of CancerShekar Shetty, PhDDiagnostics for All1:30-2:45 pmPaper-based point of CancerEdward Garmey, MDAlacrita Consulting, LLC1:30-2:45 pmInitiating HCVFreeFreeFree1:0:30 am-12 pmHIV and Cryptococcal Meningtits: Implementing a low cost point of care assay for early detection and preventionFrei Makadzange, MD, PhDRagon Institute/MGH2016I:2:30 pmHow to get insurance companies to pay for your drugs: Formulating a strategyDavid BalekdjianBruckner Group2: | | | 10:45 am-12 pm | | Peter Shaw, PhD | |
| 20163-4:30 pmImaging as a biomarker/diagnosticJohn Chen, MD, PhDMGHDay 9: THU 23rd June, 2016NMEFAlzheimer's Disease case presentation and wrap upTBDTBD1:30-2:45 pmPaper-based point of care diagnosticsShekar Shetty, PhDDiagnostics for All1:30-2:45 pmPaper-based point of care diagnosticsShekar Shetty, PhDDiagnostics for All20161:30-2:45 pmPaper-based point of care diagnosticsShekar Shetty, PhDDiagnostics for All20161:30-2:45 pmPaper-based point of care diagnosticsEdward Garmey, MDAlacrita Consulting, LLC20161:30-2:45 pmPaper-based point of care diagnosticsShekar Shetty, PhDDiagnostics for All1:30-2:45 pmPaper-based point of care Ar No Enough: An Affordable Solution to Eliminating HCVAnn Kwong, PhDAlacrita Consulting, PBCTMEC1:0:30 am-12 pmHIV and Cryptococcal Meningitis: Implementing a low cost point of care assay for early detection and preventionTariro Makadzange, MD, PhDRagon Institute/MGH21061:2:30 pmHow to get insurance companies to pay for your drugs: Formulating a strategyDavid BalekdjianBruckner Group< | 22nd June, | | 1-3 pm | | Boris Juelg, MD, PhD | |
| Day 9: THU 23rd June, | | | 3-4:30 pm | | John Chen, MD, PhD | MGH |
| Day 9: THU 23rd June, 2016TMEC L-007Pame-12:30 pmpresentation and wrap up presentation and wrap up Paper-based point of care diagnosticsCatherine Dubreuit, PhDHMS Dominic Walsh, PhD20161:30-2:45 pmPaper-based point of care diagnosticsShekar Shetty, PhDDiagnostics for All20163-4:30 pmCheckpoint Inhibition in the Treatment of CancerEdward Garmey, MDAlacrita Consulting, LLCDay 10: FRI 2016TMEC L-0079-10:15 amWhy Highly Effective Drugs Are Not Enough: An Affordable Solution to Eliminating HCVAnn Kwong, PhDTREK Therapeutics, PBCDay 10: FRI 2016TMEC L-00710:30 am-12 pmHIV and Cryptococcal Meningitis: Implementing a low cost point of care assay for early detection and preventionTariro Makadzange, MD, PhDRagon Institute/MGH20161-2:30 pmHow to get insurance companies to pay for your drugs: Formulating a strategyDavid BalekdjianBruckner Group2:30-4 pmBioengineering of circulating tumor cell microchip: from concept-to-clinical trialsMehmet Toner, PhDHMS/MGH/HST | | | 9am-12:30 pm | | | |
| TMEC June, 2016TMEC L-007I:30-2:45 pmPaper-based point of care diagnosticsShekar Shetty, PhDDiagnostics for All20161:30-2:45 pmPaper-based point of care diagnosticsShekar Shetty, PhDDiagnostics for All2016-4:30 pmCheckpoint Inhibition in the Treatment of CancerEdward Garmey, MDAlacrita Consulting, LLCAlacrita Consulting, LLC-4:30 pmWhy Highly Effective Drugs Are Not Enough: An Affordable Solution to Eliminating HCVAnn Kwong, PhDTREK Therapeutics, PBCPaper-based point of care assay for early detection and preventionHIV and Cryptococcal Meningitis: Implementing a low cost point of care assay for early detection and preventionFariro Makadzange, MD, PhDRagon Institute/MGH2016-2:30 pmHow to get insurance companies to pay for your drugs: Formulating a strategyDavid BalekdjianBruckner Group2:30-4 pmBioengineering of circulating tumor cell microchip: from concept-to-clinical trialsMehmet Toner, PhDHMS/MGH/HST | | | | | | |
| June, 2016L-007I:30-2:45 pmInterference diagnosticsShekar Shetty, PhDDiagnostics for All20163-4:30 pmCheckpoint Inhibition in the Treatment of CancerEdward Garmey, MDAlacrita Consulting, LLCDay 10: FRI 2016TMEC L-0079-10:15 amWhy Highly Effective Drugs Are Not Enough: An Affordable Solution to Eliminating HCVAnn Kwong, PhDTREK Therapeutics, PBC10:30 am-12 pmHIV and Cryptococcal Meningitis: Implementing a low cost point of care assay for early detection and preventionTariro Makadzange, MD, PhDRagon Institute/MGH201610:30 am-12 pmHow to get insurance companies to pay for your drugs: Formulating a strategyDavid BalekdjianBruckner Group2:30-4 pmBioengineering of circulating tumor cell microchip: from concept-to-clinical trialsMehmet Toner, PhDHMS/MGH/HST | | | | | Dominic Walsh, PhD | |
| 20163-4:30 pmCheckpoint Inhibition in the Treatment of CancerEdward Garmey, MDAlacrita Consulting, ILCDay 10: FRI 20169-10:15 amWhy Highly Effective Drugs Are Not Enough: An Affordable Solution to Eliminating HCVAnn Kwong, PhDTREK Therapeutics, PBCInterpret and the state of the | June, | | 1:30-2:45 pm | | Shekar Shetty, PhD | Diagnostics for All |
| Day 10: FRI 2016ParticipanAre Not Enough: An Affordable Solution to Eliminating HCVAnn Kwong, PhDTREK Therapeutics, PBCIn:30 am-12 pmHIV and Cryptococcal Meningitis: Implementing a low cost point of care assay for early detection and preventionTariro Makadzange, MD, PhDRagon Institute/MGHIn:30 am-12 pmHow to get insurance companies to pay for your drugs: Formulating a strategyDavid BalekdjianBruckner Group20162:30-4 pmBioengineering of circulating tumor cell microchip: from concept-to-clinical trialsMehmet Toner, PhDHMS/MGH/HST | | | 3-4:30 pm | Checkpoint Inhibition in the | Edward Garmey, MD | C , |
| Day 10: FRI 24th June, 2016TMEC L-00710:30 am-12 pmMeningitis: Implementing a low cost point of care assay for early detection and preventionTariro Makadzange, MD, PhDRagon Institute/MGH20161-2:30 pmHow to get insurance companies to pay for your drugs: Formulating a strategyDavid BalekdjianBruckner Group2:30-4 pmBioengineering of circulating tumor cell microchip: from concept-to-clinical trialsMehmet Toner, PhDHMS/MGH/HST | FRI 24th June, | TMEC L-007 | 9-10:15 am | Are Not Enough: An Affordable Solution to | Ann Kwong, PhD | TREK Therapeutics, PBC |
| 2016 I-2:30 pm How to get insurance companies to pay for your drugs: Formulating a strategy David Balekdjian Bruckner Group 2:30-4 pm Bioengineering of circulating tumor cell microchip: from concept-to-clinical trials Mehmet Toner, PhD HMS/MGH/HST | | | 10:30 am-12 pm | Meningitis: Implementing a low cost point of care assay for early detection and prevention | Tariro Makadzange, MD, PhD | |
| 2:30-4 pm tumor cell microchip: from Mehmet Toner, PhD HMS/MGH/HST concept-to-clinical trials | | | 1-2:30 pm | companies to pay for your | David Balekdjian | Bruckner Group |
| | | | 2:30-4 pm | tumor cell microchip: from | Mehmet Toner, PhD | HMS/MGH/HST |

(1) HMS - Harvard Medical School, BWH - Brigham and Women's Hospital, MGH - Massachusetts General Hospital, DFCI, Dana Farber Cancer Institute, BCH - Boston Children's Hospital, BIDMC - Beth Israel Deaconess Medical Center MIT - Massachusetts Institute of Technology, HST - Harvard/MIT Division of Health Sciences and Technology HSPH - Harvard School of Public Health